View Future GrowthRelmada Therapeutics 과거 순이익 실적과거 기준 점검 0/6Relmada Therapeutics의 수입은 연평균 -21.1%의 비율로 감소해 온 반면, Pharmaceuticals 산업의 수입은 연간 8.3% 증가했습니다.핵심 정보-21.09%순이익 성장률-4.77%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률7.33%매출 성장률n/a자기자본이익률-181.60%순이익률n/a최근 순이익 업데이트30 Sep 2024최근 과거 실적 업데이트Relmada Therapeutics, Inc. to Report Q4, 2025 Results on Mar 19, 2026Mar 12Relmada Therapeutics, Inc. to Report Q3, 2025 Results on Nov 13, 2025Nov 08Relmada Therapeutics, Inc. to Report Q2, 2025 Results on Aug 07, 2025Jul 31Relmada Therapeutics, Inc. to Report Q1, 2025 Results on May 12, 2025May 08Relmada Therapeutics, Inc. to Report Q4, 2024 Results on Mar 27, 2025Mar 26Relmada Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024Nov 05모든 업데이트 보기Recent updatesRelmada Therapeutics, Inc., Annual General Meeting, May 27, 2026Apr 09Relmada Therapeutics, Inc. announced that it has received $159.999996 million in funding from a group of investorsMar 13Relmada Therapeutics, Inc. to Report Q4, 2025 Results on Mar 19, 2026Mar 12Relmada Therapeutics Reports 12-Month Phase 2 Interim Data For NDV-01 In Non-Muscle Invasive Bladder CancerMar 10Relmada Therapeutics, Inc. announced that it expects to receive $159.999996 million in funding from a group of investorsMar 09Relmada Therapeutics, Inc. Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate IndicationsJan 13Relmada Therapeutics, Inc. to Report Q3, 2025 Results on Nov 13, 2025Nov 08Relmada Therapeutics, Inc. Announces Fda Feedback Supporting 2 Separate Acceptable Registrational Study Paths for Ndv-01 in Non-Muscle Invasive Bladder CancerNov 06Relmada Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000085 million.Nov 04Relmada Therapeutics, Inc. Appoints Distinguished Urologic Oncologist, Max Kates, Md, to the Clinical Advisory BoardOct 07Relmada Therapeutics, Inc. to Report Q2, 2025 Results on Aug 07, 2025Jul 31The Nasdaq Stock Market Approves Relmada Therapeutics' Application to Transfer its Listing to the Nasdaq Capital MarketJul 24Relmada Therapeutics, Inc. Appoints Yair Lotan as to Chair of its Clinical Advisory BoardJul 17Relmada Therapeutics, Inc. Appoints Raj S. Pruthi as Chief Medical Officer-UrologyJun 18Relmada Therapeutics, Inc. to Report Q1, 2025 Results on May 12, 2025May 08Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025Apr 29Relmada Therapeutics, Inc., Annual General Meeting, May 23, 2025Apr 14Relmada Therapeutics, Inc. to Report Q4, 2024 Results on Mar 27, 2025Mar 26Relmada Therapeutics Receives Written Notification from Nasdaq Regarding Minimum Bid Price RequirementJan 28Relmada Therapeutics, Inc. Elects Paul Kelly as Chief Operating OfficerJan 07Relmada Therapeutics to Discontinue the Reliance Ii and Relight Phase 3 Studies of Rel-1017Dec 10Relmada Therapeutics, Inc. Announces Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint with Statistical SignificanceDec 04Relmada Therapeutics, Inc. Initiates Phase 1 Dosing with Rel-P11 for Metabolic DiseaseNov 15New major risk - Financial position Nov 09New major risk - Revenue and earnings growth Nov 08Relmada Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024Nov 05CEO & Director recently bought €359k worth of stock Sep 12New major risk - Share price stability Aug 09New major risk - Revenue and earnings growth Aug 08Relmada Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024Aug 05New major risk - Revenue and earnings growth May 09Relmada Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024May 08Relmada Therapeutics, Inc., Annual General Meeting, May 24, 2024Apr 10Relmada Therapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024Mar 13CEO & Director recently bought €356k worth of stock Feb 01Relmada Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023Nov 04Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023Oct 12Relmada Therapeutics, Inc. Announces Dosing of First Patient in Relight, a Phase 3 Trial of Relight, a Phase 3 Trial of Relight for the Adjunctive Treatment of Major Depressive DisorderAug 24New major risk - Revenue and earnings growth Aug 10Relmada Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023Aug 03Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell Small Cap Comp Value IndexJun 25+ 1 more updateRelmada Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023May 09Relmada Therapeutics, Inc. Appoints Fabiana Fedeli to Board of DirectorsJan 13Relmada Therapeutics, Inc. Appoints Cedric O'Gorman MD as Chief Medical OfficerJan 10CEO & Director recently bought €110k worth of stock Dec 14Relmada Therapeutics, Inc. Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive DisorderDec 08High number of new and inexperienced directors Nov 16Relmada Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022Nov 09Relmada Therapeutics Inc. Announces Top-line Results from Phase 3 RELIANCE III Trial for REL 1017 as a Monotherapy for the Treatment of Major Depressive DisorderOct 14Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 Reliance III Trial for REL-1017 as A Monotherapy for Major Depressive DisorderSep 21Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive DisorderAug 10Relmada Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022Aug 06Relmada Therapeutics, Inc. Appoints John Hixon as Head of CommercialJul 22Relmada Therapeutics, Inc. Announces Publication of REL-1017 Preclinical Data in Frontiers in PharmacologyMay 02High number of new and inexperienced directors Apr 27Relmada Therapeutics, Inc., Annual General Meeting, May 25, 2022Apr 12Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 VS Ketamine for Abuse PotentialFeb 24Relmada Therapeutics, Inc. Announces Publication of Rel-1017 Phase 2 Study Results in the American Journal of PsychiatryDec 23Relmada Therapeutics, Inc. Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021Apr 28Relmada Therapeutics, Inc. to Report Q4, 2020 Results on Mar 23, 2021Mar 19New 90-day high: €31.40 Feb 18New 90-day high: €30.80 Jan 14Relmada Therapeutics, Inc. Announces Resignation of Thomas Wessel as Executive Vice President and Head of Research and DevelopmentJan 06Relmada Therapeutics, Inc. Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive DisorderDec 10Relmada Therapeutics Announces Appointments of New ExecutiveOct 29New 90-day low: €28.20 Oct 21매출 및 비용 세부 내역Relmada Therapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BST:4E2 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 240-86425030 Jun 240-87424931 Mar 240-94465231 Dec 230-99495530 Sep 230-112496730 Jun 230-129458731 Mar 230-1444710431 Dec 220-1574811330 Sep 220-1534511230 Jun 220-1574511531 Mar 220-1434010231 Dec 210-126359130 Sep 210-112327930 Jun 210-86295731 Mar 210-71284431 Dec 200-59253430 Sep 200-43222330 Jun 200-30181231 Mar 200-23111131 Dec 190-157830 Sep 190-185730 Jun 190-175731 Mar 190-176531 Dec 180-175530 Sep 180-114430 Jun 180-94331 Mar 180-74231 Dec 170-65130 Sep 170-65130 Jun 170-66131 Mar 170-87231 Dec 160-87230 Sep 160-99430 Jun 160-310631 Mar 16069831 Dec 150691030 Sep 1501481030 Jun 150-219831 Mar 150-5519931 Dec 140-4617430 Sep 140-5616630 Jun 140-28135양질의 수익: 4E2 은(는) 현재 수익성이 없습니다.이익 마진 증가: 4E2는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 4E2은 수익성이 없으며 지난 5년 동안 손실이 연평균 21.1% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 4E2의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 4E2은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(12.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 4E2는 현재 수익성이 없으므로 자본 수익률이 음수(-181.6%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/03/04 14:43종가2024/12/05 00:00수익2024/09/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Relmada Therapeutics, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Maxim JacobsEdison Investment ResearchFarzin HaqueJefferies LLCAndrew BerensLeerink Partners LLC7명의 분석가 더 보기
Relmada Therapeutics, Inc. announced that it has received $159.999996 million in funding from a group of investorsMar 13
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data For NDV-01 In Non-Muscle Invasive Bladder CancerMar 10
Relmada Therapeutics, Inc. announced that it expects to receive $159.999996 million in funding from a group of investorsMar 09
Relmada Therapeutics, Inc. Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate IndicationsJan 13
Relmada Therapeutics, Inc. Announces Fda Feedback Supporting 2 Separate Acceptable Registrational Study Paths for Ndv-01 in Non-Muscle Invasive Bladder CancerNov 06
Relmada Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000085 million.Nov 04
Relmada Therapeutics, Inc. Appoints Distinguished Urologic Oncologist, Max Kates, Md, to the Clinical Advisory BoardOct 07
The Nasdaq Stock Market Approves Relmada Therapeutics' Application to Transfer its Listing to the Nasdaq Capital MarketJul 24
Relmada Therapeutics Receives Written Notification from Nasdaq Regarding Minimum Bid Price RequirementJan 28
Relmada Therapeutics, Inc. Announces Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint with Statistical SignificanceDec 04
Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023Oct 12
Relmada Therapeutics, Inc. Announces Dosing of First Patient in Relight, a Phase 3 Trial of Relight, a Phase 3 Trial of Relight for the Adjunctive Treatment of Major Depressive DisorderAug 24
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell Small Cap Comp Value IndexJun 25+ 1 more update
Relmada Therapeutics, Inc. Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive DisorderDec 08
Relmada Therapeutics Inc. Announces Top-line Results from Phase 3 RELIANCE III Trial for REL 1017 as a Monotherapy for the Treatment of Major Depressive DisorderOct 14
Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 Reliance III Trial for REL-1017 as A Monotherapy for Major Depressive DisorderSep 21
Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive DisorderAug 10
Relmada Therapeutics, Inc. Announces Publication of REL-1017 Preclinical Data in Frontiers in PharmacologyMay 02
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 VS Ketamine for Abuse PotentialFeb 24
Relmada Therapeutics, Inc. Announces Publication of Rel-1017 Phase 2 Study Results in the American Journal of PsychiatryDec 23
Relmada Therapeutics, Inc. Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021Apr 28
Relmada Therapeutics, Inc. Announces Resignation of Thomas Wessel as Executive Vice President and Head of Research and DevelopmentJan 06
Relmada Therapeutics, Inc. Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive DisorderDec 10